Radiation Therapy: IMRT/IGRT/SBRT/3D/2D

USMD Cancer Center features advanced, state-of-the-art radiation therapy technologies that enable precise targeting of the prostate, while minimizing dose to adjacent critical structures such as the bladder and rectum.

TrueBeam STX & NovalisTX Radiosurgery SystemsTrueBeam STX & NovalisTX Radiosurgery Systems

The TrueBeam STX and the Novalis TX systems provide equivalent precision for treating prostate cancer. At the USMD Cancer Center, standard IMRT is no longer utilized. Both machines are equipped with CT scans that provide image guidance. This allows for an accurate patient set up in 3D, prior to the delivery of treatment. In fact, prior to the delivery of each treatment, the patient’s set up is reviewed and approved by the radiation oncologist, providing highest level of quality assurance.

IMRT has traditionally been delivered using 5 to 7 static fields. At USMD, Rapidarc technology is utilized for treatment. This 360 degree approach has markedly improved beam shaping and achieved a significant dose reduction to the bladder and rectum, minimizing side effects.

This powerful new IGRT technology can treat prostate cancer with incredible precision and control, and is a completely non-invasive treatment with no pain or recovery time involved!

Varian TrueBeam™ Radiation TherapyVarian TrueBeam™ Radiation Therapy

The Varian TrueBeam™ is equipped with several unique features to address specific diagnoses and the most complex and demanding cases.  While the majority of treatments are delivered to patients with prostate cancer, we do treat bladder cancer, kidney cancer and metastatic disease. 

3D treatment may be used for bladder cancer, and 2D for simple bone metastases.

Stereotactic body radiation therapy (SBRT) is utilized to treat kidney cancer (when patients can’t tolerate surgery) and to treat metastatic disease to spine, lung and brain.  The TrueBeam is equipped with a whole body infrared, real-time imaging system enabling the safe delivery of high dose, short treatment courses with sub-millimeter accuracy. 

Frequently Asked Questions

Are Family Members at Risk of Receiving Radiation during my treatment?

When a patient receives external beam radiation therapy, they are not “radioactive”. In other words, when the exit the treatment room they provide no radiation risk to the general public, fellow employees, family, children or pets.

Will I receive Hormone therapy as part of my treatment?

At the time of consultation, the radiation oncologist will review findings with the patient and explain classifications and guidelines. Patients are typically stratified into low, intermediate and high risk groups. Intermediate risk patients may receive short-term hormone therapy in conjunction with IGRT. High risk patients most often receive long-term hormone therapy in conjunction with IGRT.

Can I work during radiation therapy?

Almost all patients undergoing IMRT with Rapidarc for prostate cancer are able to live their lives without restrictions. Work, recreation, and social life are typically pursued without significant interruption. On very rare occasion, a patient's energy level, ability to concentrate and ability to function may be affected to a degree that makes a full time employment overly demanding.

Will I be incontinent after radiation therapy?

When state-of-the-art equipment (Novalis or TrueBeam) and modern techniques (IMRT, image guidance, Rapidarc) are utilized, the risk of incontinence is limited to approximately 0-1%. Patients who have undergone prior procedures such as a radical prostatectomy, TURP or cryotherapy will have a higher risk of developing incontinence. If bothersome incontinence develops, surgical correction may be considered. You may also want to ask your doctor about medication that may help with this problem.

Peter LaNasa, M.D.
Dr. LaNasa is a board certified radiation oncologist, sub-specializing in urologic malignancies and stereotactic body radiation therapy.
Click here to read full bio
Urology Website Design | Websites for Doctors Urologists by Vital Element, Inc.